Coronado Industries Receives China Patents for its Glaucoma Treatment Technology; Starts Discussions with Potential Distributors.

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTCBB: CDIK), the manufacturer of unique proprietary pneumatic devices for the treatment of glaucoma, announced today that the company has received patents for its PNT treatment device and procedure in China.

In making the announcement, Coronado's CEO, Richard Smith, said the company had meetings in New York last week with a major Beijing-based facilitator with a view to bringing the device and cost-saving benefits to the Chinese health authorities and establishing distribution in China. "It represents an enormous market for Coronado's technology, and receipt of the patents marks another big step forward in our international marketing plans," he said. "Since our meeting last week, we have had a positive response back from principals in both the national health system and the private sector. We are definitely moving forward."

John Sharkey, Coronado's director of development, said it was estimated that 9.4 million people age 40 years and older in China have glaucomatous optic neuropathy and that of this number, 5.2 million (55%) are blind in at least one eye and 1.7 million (18.1%) are blind in both eyes.

Dr. Sharkey said the company was intent on establishing representation in a number of overseas markets. "We have already begun shipping products to distributors in Italy, Spain and Portugal and negotiations are underway to establish further distribution rights in a number of other countries. You may be sure that we shall be looking very closely into the many opportunities that China presents," he said.

Coronado Industries has, for seven years, been dedicated to its patented Glaucoma Treatment Device. Through its wholly owned subsidiary, Ophthalmic International, it focuses on the development of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.